Chugai Pharmaceutical Co., Ltd. (4519.T) vs Takeda Pharmaceutical Company Limited (TAK)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| 4519.T | TAK | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| Size band | LARGE | LARGE |
| Listing | Tokyo | NYSE |
| Country | Japan | Japan |
| Theme | oncology | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | 6,795.00 JPY | $20.43 |
| Return · 1 week | +5.68% | +4.18% |
| Return · 1 month | +6.81% | +8.10% |
| Return · 3 months | −3.88% | +16.61% |
| Return · year to date | −20.21% | +30.79% |
| Return · 1 year | +1.90% | +44.18% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −36.50% | −0.59% |
| 52-week high | 10,700.00 JPY | $20.55 |
| 52-week low | 5,974.00 JPY | $12.99 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $72.04B | $65.27B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $17.60B | $48.63M |
| Employees | 5,104 | 47,029 |
| Valuation | ||
| Price to earnings · trailing | 21.88× | n/a (negative earnings) |
| Price to earnings · forward | 26.57× | 37.11× |
| Price to sales | 7.68× | 0.01× |
| Price to book | 5.09× | 1.30× |
| Enterprise value to EBITDA | 13.24× | 4.11× |
| Enterprise value to revenue | 6.68× | 1.11× |
| PEG ratio | 1.57 | 0.44 |
| Earnings per share · trailing | 286.42 | -0.34 |
| Profitability | ||
| Gross margin | 71.34% | 65.50% |
| Operating margin | 47.09% | 16.45% |
| Profit margin | 35.10% | −3.54% |
| Return on equity | 23.49% | −2.26% |
| Return on assets | 17.06% | 2.69% |
| Growth | ||
| Revenue growth | +17.80% | +10.20% |
| Earnings growth | +19.70% | −9.80% |
| Balance sheet and payout | ||
| Debt / equity (%) | — | 73.25 |
| Current ratio | 4.35 | 1.14 |
| Dividend yield | 2.19% | 3.13% |
| Payout ratio | 48.18% | 279.89% |
| Trend and volatility | ||
| RSI · 14 | 64.07 | 70.35 |
| ADX · 14 | 21.59 | 32.50 |
| 50-day average | 6,594.80 JPY | $18.59 |
| 200-day average | 7,836.51 JPY | $17.45 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.31% | 1.79% |
The full 4519.T analysis
Everything this table leaves out for Chugai Pharmaceutical Co., Ltd.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the 4519.T argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full 4519.T analysisThe full TAK analysis
Everything this table leaves out for Takeda Pharmaceutical Company Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the TAK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full TAK analysis